Stanley-Laman Group’s Spyre Therapeutics SYRE Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Shares Change %	Capital Flow	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,401	Closed	-$371K	–	236
2018 Q2	$371K	Buy	1,401 +923	+193%	+$244K	0.08%	232
2018 Q1	$118K	Buy	+478	New	+$118K	0.03%	259